Death risk prompts Lynparza withdrawal in gBRCAm

28 September 2022

AstraZeneca (LSE: AZN) has written to US healthcare professionals to notify them of the company’s volunatary withdrawal of an indication for Lynparza (olaparib).

The Anglo-Swedish pharma major, which has developed the PARP inhibitor alongside Merck & Co (NYSE: MRK), has taken the action in relation to the use of Lynparza for adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more lines of chemotherapy.

According to the letter, the decision was taken in consultation with the US Food and Drug Administration (FDA) after a recent subgroup analysis indicated a potential detrimental effect on overall survival for Lynparza compared to chemotherapy in these patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK